Earnings Ahead

SRPT - Sarepta Therapeutics Inc.

106.4 -1.88 -1.74

Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc.

About

Profile

Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases.


Headquarters

Cambridge, Massachusetts, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

SRPT

Recent Earnings

Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M

The bio-pharmaceutical stock advanced 1.6% after notably outperforming Wall Street expectations in the third quarter. Sarepta said it lost 46 cents per share and saw a revenue of $331.8 million. Meanwhile, Analysts anticipated a much larger loss of $1.22 per share on revenue of $285.3 million.


 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M
  • Sarepta Therapeutics Q3 2023 Earnings Preview
  • Biggest stock movers today: Caterpillar, Arista Networks, BP, Pinterest and more
  • Sarepta in selloff after late-stage setback for Duchenne candidate
  • 5 stocks to watch on Tuesday: Sarepta Therapeutics, Pfizer, AMD and more
  • Sarepta Phase 3 study for DMD drug fails to meet primary endpoint
  • Mizuho doesn't see Sarepta price decline connected to EMBARK study
  • Sarepta Therapeutics Non-GAAP EPS of -$0.85 beats by $0.15, revenue of $261.2M beats by $5.36M
  • Sarepta Therapeutics Q2 2023 Earnings Preview
  • Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023
  • Catalyst Watch: CPI, major bank earnings, Amazon Prime Day and CAVA ratings
  • Sarepta raises $102M from selling priority review voucher
  • Sarepta down 9% as Duchenne treatment gets narrow population approval
  • Sarepta Duchenne treatment wins FDA nod, but with smaller population (update)
  • Regenxbio, UPenn file second patent suit against Sarepta over DMD therapy
  • Catalyst watch: C3.ai and Salesforce earnings, Knife River debut, Kenvue ratings & Faraday Future event
  • Hot Stocks: ANF, URBN and PANW rise on earnings; A, XPEV fall on weak outlooks; OCGN slides
  • Sarepta says FDA needs more time to review muscular dystrophy drug
  • Billions of dollars at stake as FDA shortcut allows half-proven drugs - report
  • Argenx, Blueprint Medicines, Sarepta likely M&A targets - analyst
Recent Earnings

Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M

Earnings History

Date EPS / Forecast Revenue / Forecast
October 27, 2021 - / -1.83 - / 171.36M
August 4, 2021 -1.02 / -1.3 164.09M / 167.07M
May 5, 2021 -2.1 / -1.83 146.93M / 145.81M Beat!
March 1, 2021 -2.4 / -1.8 145.14M / 150.38M
November 5, 2020 -2.5 / -1.71 143.92M / 137.76M Beat!
August 5, 2020 -1.93 / -1.72 137.36M / 116.29M Beat!
May 6, 2020 -0.23 / -1.92 113.67M / 116.49M
February 26, 2020 -3.16 / -1.81 100.11M / 98.8M Beat!
November 7, 2019 -1.7 / -1.35 99.04M / 98.48M Beat!
August 7, 2019 -3.74 / -1.07 94.67M / 91.05M Beat!
May 8, 2019 -1.07 / -1.61 87.01M / 86.6M Beat!
February 27, 2019 -2.05 / -1.02 84.42M / 84.92M
October 24, 2018 -1.15 / -0.78 78.49M / 78.75M
August 8, 2018 -1.67 / -0.84 73.53M / 71.4M Beat!
May 3, 2018 -0.55 / -0.32 64.6M / 65.09M
February 26, 2018 - / -0.32 - / 55.57M
October 25, 2017 -0.76 / -0.85 45.95M / 40.77M Beat!
July 19, 2017 -0.46 / -0.77 35.01M / 22.38M Beat!
April 27, 2017 -0.71 / -0.81 16.34M / - Beat!
February 28, 2017 -0.71 / -0.45 5.42M / 46.83M
October 27, 2016 -1.18 / -0.52 - / 3.08M
Date Price Open High Low Vol Change
Dec 4 86.12 84.38
86.94
84
1.3M 1.99%
Dec 1 84.44 81.28
84.5
78.67
1.3M 3.89%
Nov 30 81.28 81.01
81.9
80.22
1.3M 1.09%
Nov 29 80.4 82.72
83.5
80.14
1.1M -2.68%
Nov 28 82.61 81.97
82.9
81.6
928K 0.04%
 
Nov 27 82.58 82.5
84.04
81.64
651K -0.35%
Nov 24 82.87 83.83
84.23
82.28
395K -1.07%
Nov 22 83.77 84.42
85.23
82.06
607K -0.37%
Nov 21 84.08 85.03
85.4
83.42
1.0M 1.23%
Nov 20 83.06 83
85.94
82.62
1.4M -0.11%
Nov 17 83.15 82.98
85.5
82.77
1.4M 0.20%
Nov 16 82.98 83.08
83.43
81.18
1.4M -0.93%
Nov 15 83.76 81.77
84.71
81.46
1.2M 1.53%
Nov 14 82.5 81.93
82.56
80.68
1.7M 3.55%
Nov 13 79.67 79.74
80.3
76.61
883K 0.28%
Nov 10 79.45 78.81
79.66
76.25
1.3M 0.38%
Nov 9 79.15 79.88
80.25
75.85
2.1M -1.91%
Nov 8 80.69 82.93
83.47
80.4
1.1M -2.7%
Nov 7 82.93 80.62
84.19
80.62
2.2M 3.53%
Nov 6 80.1 81.5
83.11
79.66
2.6M 2.68%
Nov 3 78.01 78.42
81.27
77.8
2.3M 0.32%
Nov 2 77.76 79.43
82.22
75.69
3.7M 1.62%
Nov 1 76.52 68.4
76.77
68
6.8M 13.68%
Oct 31 67.31 57.63
68
55.25
23.5M -37.47%
Oct 30 107.65 107.95
109.96
106.92
742K 0.77%
Oct 27 106.83 111.9
111.9
106.05
929K -4.27%
Oct 26 111.6 107.39
112.23
105.92
1.1M 4.07%
Oct 25 107.24 112.39
112.66
106.52
1.1M -5.45%
Oct 24 113.42 111.63
113.95
110.72
827K 1.81%
Oct 23 111.4 111
113.42
109.78
869K 0.18%
Oct 20 111.2 113.18
113.96
111
1.0M -1.59%
Oct 19 113 114.55
114.99
111.78
743K -0.72%
Oct 18 113.82 118.32
118.32
112.77
938K -4.07%
Oct 17 118.65 117
119.99
116.57
710K 0.94%
Oct 16 117.55 117.75
119.06
116.44
651K -0.35%
Oct 13 117.96 116.7
118.73
114.12
780K 0.64%
Oct 12 117.21 125
125
116.82
1.1M -6.05%
Oct 11 124.76 122.9
124.85
122.4
782K 1.55%
Oct 10 122.86 123.4
124.01
121.5
1.4M -0.46%
Oct 9 123.43 122.97
124.1
121.12
1.0M -0.41%
Oct 6 123.94 120.79
124.16
119.85
879K 2.08%
Oct 5 121.41 117.89
122.65
117
1.1M 3.06%
Oct 4 117.81 119.99
120.63
116.82
1.3M -2.19%
Oct 3 120.45 117.97
121.07
117.71
916K 1.57%
Oct 2 118.59 120.4
121.67
118.09
917K -2.17%
Sep 29 121.22 124
124.1
120.84
782K -1.92%
Sep 28 123.59 122.94
124.51
121.31
937K 0.12%
Sep 27 123.44 120.52
124.15
119.34
858K 3.37%
Sep 26 119.41 114.92
119.94
114.92
805K 4.07%
Sep 25 114.74 120
120.3
110.56
1.7M -4.33%
Sep 22 119.93 120
121.82
119.65
553K 0.32%
Sep 21 119.55 117.32
119.79
117.27
828K 1.34%
Sep 20 117.97 118.85
118.85
117.41
721K -0.96%
Sep 19 119.11 118.66
120.11
118.1
727K 0.90%
Sep 18 118.05 117.79
118.65
116.98
705K -0.3%
Sep 15 118.4 119.4
120.05
117.4
1.0M -1.1%
Sep 14 119.72 119.47
120.48
119
629K 0.62%
Sep 13 118.98 119.69
120.53
118.03
536K -0.73%
Sep 12 119.85 118.03
120.79
117.88
642K 1.22%
Sep 11 118.4 120.05
120.63
118.22
801K 0%